<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39347">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594163</url>
  </required_header>
  <id_info>
    <org_study_id>SGN35-023</org_study_id>
    <nct_id>NCT02594163</nct_id>
  </id_info>
  <brief_title>Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma</brief_title>
  <official_title>A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, multicenter, Phase 2 clinical trial designed to evaluate
      the efficacy and safety of brentuximab vedotin in combination with rituximab and
      bendamustine for the treatment of patients with relapsed or refractory CD30-positive diffuse
      large B-cell lymphoma (DLBCL) after failure of second-line salvage therapy or as second-line
      treatment in patients ineligible for autologous stem cell transplant (ASCT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized in a 1:1 manner to receive rituximab plus bendamustine with or
      without brentuximab vedotin. Patients who respond to combination treatment containing
      brentuximab vedotin and do not experience excessive toxicity may receive additional
      single-agent brentuximab vedotin following combination treatment, for up to an additional 10
      cycles (up to 16 total cycles of treatment).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The objective response rate (ORR)</measure>
    <time_frame>Up to approximately 12 months (at End of Treatment (EoT) visit)</time_frame>
    <description>A comparison between the 2 arms of imaging (Computed tomography(CT) and Positron emission tomography (PET) or CT/PET; PET no longer required after documented postbaseline [18F]fluorodeoxyglucose-negative PET)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to approximately 4 years 3 months</time_frame>
    <description>A comparison between the 2 arms of first documentation of disease progression/relapse, or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission (CR) rate</measure>
    <time_frame>Up to approximately 12 months (at End of Treatment (EoT) visit)</time_frame>
    <description>A comparison between the 2 arms of first documentation of disease progression/relapse, or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to approximately 4 years 3 months</time_frame>
    <description>A comparison between the 2 arms of the time from first observation of response (Partial remission (PR)/Partial metabolic response (PMR)+Complete remission (CR)/Complete metabolic response (CMR)) to disease progression/relapse or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 4 years 3 months</time_frame>
    <description>A comparison between the 2 arms of the time from first dose of study medication to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>Through 30-37 days following last dose (at end of treatment visit).</time_frame>
    <description>A comparison of adverse events between the 2 arms in the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Diffuse Large B-cell Lymphoma Refractory</condition>
  <condition>Follicular B-cell Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Brentuximab Vedotin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the brentuximab vedotin arm will receive IV infusions of brentuximab vedotin followed by bendamustine on day 1, and rituximab followed by bendamustine on day 2 of each 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab,Bendamustine control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to the control arm will receive IV infusions of rituximab on day 1 or day 2 and bendamustine on both days 1 and 2 of each 21 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab Vedotin</intervention_name>
    <arm_group_label>Brentuximab Vedotin</arm_group_label>
    <other_name>Adcetris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Brentuximab Vedotin</arm_group_label>
    <arm_group_label>Rituximab,Bendamustine control</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <arm_group_label>Brentuximab Vedotin</arm_group_label>
    <arm_group_label>Rituximab,Bendamustine control</arm_group_label>
    <other_name>Treanda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with confirmed CD30-positive DLBCL or grade 3b follicular non-Hodgkin
             lymphoma (NHL).

          2. Patients must have relapsed or refractory disease following:

               1. second-line or greater salvage systemic therapy, or

               2. frontline cytotoxic systemic therapy, for patients who are ineligible for stem
                  cell transplant (SCT).

          3. Age 18 years and older.

          4. Fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET).

          5. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.

          6. Acceptable blood test results.

          7. Females of childbearing potential must have a negative pregnancy test result within 7
             days prior to the first dose of study drug.

          8. Females of childbearing potential and males who have partners of childbearing
             potential must agree to use an effective contraceptive method during the study and
             for 6 months following the last dose of brentuximab vedotin or 12 months following
             the last dose of rituximab, whichever is later.

          9. Patients must provide written informed consent.

        Exclusion Criteria:

          1. History of another invasive malignancy that has not been in remission for at least 1
             year. (Exceptions are nonmelanoma skin cancer, curatively treated localized prostate
             cancer, ductal carcinoma, and cervical carcinoma or a squamous intraepithelial lesion
             on PAP smear).

          2. History of progressive multifocal leukoencephalopathy (PML).

          3. Cerebral/meningeal disease related to the underlying malignancy, unless definitively
             treated.

          4. Viral, bacterial, or fungal infection within 2 weeks prior to the first dose of
             treatment.

          5. Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with
             immunotherapy that is not completed 4 weeks prior to first dose of study drug.

          6. Females who are pregnant or breastfeeding.

          7. Known allergy to any study drug or ingredient contained in the drug formulation of
             any of the study drugs.

          8. Known to be positive for hepatitis B. Known to have active hepatitis C infection or
             on antiviral therapy for hepatitis C within the last 6 months.

          9. Known to be positive for human immunodeficiency virus (HIV).

         10. Patients with previous allogeneic stem cell transplant.

         11. Previous treatment with brentuximab vedotin or bendamustine.

         12. Intolerable toxicity to prior rituximab therapy.

         13. Current therapy with other investigational agents.

         14. Lung disease unrelated to underlying malignancy.

         15. History of a stroke or transient ischemic attack, unstable angina, myocardial
             infarction, or cardiac symptoms within 6 months prior to the first dose of treatment.

         16. Congestive heart failure.

         17. Significant peripheral sensory or motor neuropathy at the start of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Ruffner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nikki Bindra, BDS</last_name>
    <phone>+1 434 951 3969</phone>
    <email>BindraNikki@prahs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Kyung</last_name>
      <phone>626-256-4673</phone>
      <email>ckyung@coh.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Budde</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sansum Clinic - West Pueblo</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Heitkamp</last_name>
      <phone>805-563-5800</phone>
      <email>hheitkam@ccsb.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Greenwald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruma Barva</last_name>
      <phone>310-989-7757</phone>
      <email>rbarva@scoranet.org</email>
    </contact>
    <investigator>
      <last_name>Lasika Seneviratne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Szmagalski</last_name>
      <phone>562-693-4477</phone>
      <email>mszmagalski@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Richy Agajanian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Morris</last_name>
      <phone>303-386-7609</phone>
      <email>karen.morris@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>John Burke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oncology</name>
      <address>
        <city>Lonetree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Bourie</last_name>
      <phone>303-649-5281</phone>
      <email>PATRICIA.L.BOURIE@KP.ORG</email>
    </contact>
    <investigator>
      <last_name>Alexander Menter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbeth Lynn</last_name>
      <phone>847-827-9060</phone>
      <email>lisbeth.lynn@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Leonard Klein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juli Brown</last_name>
      <phone>502-629-3673</phone>
      <email>Juli.brown3@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Don Stevens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashley Newcomb</last_name>
      <phone>617-632-7970</phone>
      <email>AshleyN_Newcomb@DFCI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Eric Jacobsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Uryga</last_name>
      <phone>313-576-8624</phone>
      <email>urygaa@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Radhakrishnan Ramchandren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Imlay</last_name>
      <phone>314-577-8854</phone>
      <email>aimlay@slu.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Fesler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Cancer Treatment Center</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Hadenfeldt</last_name>
      <phone>308-398-6783</phone>
      <email>rhadenfeldt@sfmc-gi.org</email>
    </contact>
    <investigator>
      <last_name>Mehmet Copur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology Associates of Northern New Jersey, P.A.</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mackenzie</last_name>
      <phone>973-538-3593</phone>
      <phone_ext>2338</phone_ext>
      <email>mmackenzie@regionalcancercare.org</email>
    </contact>
    <investigator>
      <last_name>Charles Farber, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanne Schaffer</last_name>
      <phone>541-741-3451</phone>
      <email>jeanne.schaffer@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Yasenchak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Saint Francis Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Stoeppler-Biege</last_name>
      <phone>864-449-0444</phone>
      <email>kristina_stoeppler-biege@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Howland Crosswell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Institutional Review Board</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Norris</last_name>
      <phone>864-241-6251</phone>
      <email>gnorris@ghs.org</email>
    </contact>
    <investigator>
      <last_name>Suzanne Fanning, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blake Pond</last_name>
      <phone>214-648-7030</phone>
      <email>blake.pond@utsw.edu</email>
    </contact>
    <investigator>
      <last_name>Madhuri Vusirikala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Flower Mound</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Langston</last_name>
      <phone>972-537-4100</phone>
      <email>jamie.langston@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Dennis Costa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ebony Villarson</last_name>
      <phone>757-466-8683</phone>
      <email>ebony.villarson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Scott Cross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia, Inc.</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Holt</last_name>
      <phone>540-982-0237</phone>
      <email>natasha.holt@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jennifer Vaughn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Clinical Research</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Edelheit</last_name>
      <phone>206-342-6920</phone>
      <email>beth.edelheit@virginiamason.org</email>
    </contact>
    <investigator>
      <last_name>David Aboulafia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UW Cancer Center at ProHealth Care</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chanda Miller</last_name>
      <phone>262-928-5539</phone>
      <email>chanda.miller@phci.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Wassenaar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FN Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00 420 532 233 641</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00 420 495 832 686</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Královské Vinohrady</name>
      <address>
        <city>Praha</city>
        <zip>100</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00 420 267 16 2292</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Universitaire (CHRU) Brest - Hopital Morvan</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0033298223421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Côte de Nacre - Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0033231272107</phone>
      <email>ihbn@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier des Oudairies</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0033251446173</phone>
      <email>oncohemato@chd-vendee.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Mans</name>
      <address>
        <city>Le Rocher</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHR Metz</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0033387553304</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes (CHU Nantes) - Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>000240083253</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Perpignan</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0033468618879</phone>
      <email>secretariat.hematologie@ch-perpignan.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) de Poitier- Hopital de la Miletrie - Hopital Jean Bernard</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0033549444307</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0033299289756</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0039051390413</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00390303995747</phone>
      <email>ematologia@spedalicivili.brescia.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCSS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00390382503084</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico Umberto I di Roma</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00390882410295</phone>
      <email>ematologia@operapadrepio.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O Ospadale Di Circolo E Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00390332278115</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny</name>
      <address>
        <city>Łódź</city>
        <zip>93-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00 34 93 556 56 49</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00 34 91 191 78 09</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00 34 963 86 27 45</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa de Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>00 34 976 76 88 70</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital's Birmingham NHS Foundation trust-Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liverpool and Broadgreen Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0151 706 2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maidstone and Tunbridge Wells NHS Trust</name>
      <address>
        <city>Maidstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>01622 729000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0161 446 3000</phone>
    </contact>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>December 1, 2016</lastchanged_date>
  <firstreceived_date>October 30, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
